drugset
drugset / Trial / NCT07377591

A Study of HDM2006 in Patients With Advanced Solid Tumor

NCT07377591 ↗

Phase 1 Recruiting 48 enrolled Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2006 in patients with advanced solid tumors.

Timeline

Start
2024-12-31
Primary completion
2026-09
Completion
2027-03

Drugs

EvaluationDrugModalityDoseRoute
Subject HDM2006 Unknown 50 mg Oral
Subject HDM2006 Unknown 1000 mg Oral

Indications

cancer